The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma

Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5...

Full description

Saved in:
Bibliographic Details
Published in:Diseases 2018-11, Vol.6 (4), p.103
Main Authors: Parkin, Ashleigh, Man, Jennifer, Chou, Angela, Nagrial, Adnan M, Samra, Jaswinder, Gill, Anthony J, Timpson, Paul, Pajic, Marina
Format: Article
Language:English
Subjects:
Abdomen
Adenocarcinoma
Biomarkers
Cancer therapies
Cell cycle
Chemoresistance
Clinical trials
Gene expression
Genomics
Lymphatic system
Malignancy
Medical prognosis
Metastasis
molecular classification
Mutation
Pain
Pancreatic cancer
Patients
Precision medicine
Review
tailored therapy
Tumors
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83
cites cdi_FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83
container_end_page
container_issue 4
container_start_page 103
container_title Diseases
container_volume 6
creator Parkin, Ashleigh
Man, Jennifer
Chou, Angela
Nagrial, Adnan M
Samra, Jaswinder
Gill, Anthony J
Timpson, Paul
Pajic, Marina
description Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapy depending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies.
doi_str_mv 10.3390/diseases6040103
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e79a8988ae334d61a082632833f8acf3</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e79a8988ae334d61a082632833f8acf3</doaj_id><sourcerecordid>2133823336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83</originalsourceid><addsrcrecordid>eNpdkk1vEzEQhi0EolXomRtaiQuXUK9nP-wLUtUWqBQEh_ZsTezZ1JFjB3s3Ev8eLylVW1_G8_rxq5nRMPa-5p8BFD-3LhNmyh1veM3hFTsVvFdL1Yv69ZP7CTvLecvLUTVI0b1lJ8AbIdu-OWXu9p6q60P0Bxc21V2wlPKIwc5ZHKqxvP6InszkMVVFrwqfcE_T6Ey1KkI2JZvRXxhMIpz1q8mM6KsLSyEaTMaFuMN37M2APtPZQ1ywu6_Xt5ffl6uf324uL1ZLAyBgCetGKuq4IWnWIFu1VgNJ1SrZcmONEIaTEn3TShIN70iUaAXyWtIgcJCwYDdHXxtxq_fJ7TD90RGd_ifEtNGYSpWeNPUKpZISCaCxXY28jAeEBBgkmgGK15ej135a78gaCmNC_8z0-Utw93oTD7qDGqCbDT49GKT4e6I86p3LhrzHQHHKWhRMCpjZBfv4At3GKYUyKi1aKXolGz53d36kTIo5Jxoei6m5nrdCv9iK8uPD0x4e-f87AH8Bfwq0pw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2582798408</pqid></control><display><type>article</type><title>The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Parkin, Ashleigh ; Man, Jennifer ; Chou, Angela ; Nagrial, Adnan M ; Samra, Jaswinder ; Gill, Anthony J ; Timpson, Paul ; Pajic, Marina</creator><creatorcontrib>Parkin, Ashleigh ; Man, Jennifer ; Chou, Angela ; Nagrial, Adnan M ; Samra, Jaswinder ; Gill, Anthony J ; Timpson, Paul ; Pajic, Marina</creatorcontrib><description>Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapy depending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies.</description><identifier>ISSN: 2079-9721</identifier><identifier>EISSN: 2079-9721</identifier><identifier>DOI: 10.3390/diseases6040103</identifier><identifier>PMID: 30428574</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Abdomen ; Adenocarcinoma ; Biomarkers ; Cancer therapies ; Cell cycle ; Chemoresistance ; Clinical trials ; Gene expression ; Genomics ; Lymphatic system ; Malignancy ; Medical prognosis ; Metastasis ; molecular classification ; Mutation ; Pain ; Pancreatic cancer ; Patients ; Precision medicine ; Review ; tailored therapy ; Tumors ; Ultrasonic imaging</subject><ispartof>Diseases, 2018-11, Vol.6 (4), p.103</ispartof><rights>2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018 by the authors. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83</citedby><cites>FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83</cites><orcidid>0000-0002-3871-3829</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2582798408/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2582798408?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30428574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parkin, Ashleigh</creatorcontrib><creatorcontrib>Man, Jennifer</creatorcontrib><creatorcontrib>Chou, Angela</creatorcontrib><creatorcontrib>Nagrial, Adnan M</creatorcontrib><creatorcontrib>Samra, Jaswinder</creatorcontrib><creatorcontrib>Gill, Anthony J</creatorcontrib><creatorcontrib>Timpson, Paul</creatorcontrib><creatorcontrib>Pajic, Marina</creatorcontrib><title>The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma</title><title>Diseases</title><addtitle>Diseases</addtitle><description>Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapy depending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies.</description><subject>Abdomen</subject><subject>Adenocarcinoma</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Chemoresistance</subject><subject>Clinical trials</subject><subject>Gene expression</subject><subject>Genomics</subject><subject>Lymphatic system</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>molecular classification</subject><subject>Mutation</subject><subject>Pain</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Review</subject><subject>tailored therapy</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><issn>2079-9721</issn><issn>2079-9721</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1vEzEQhi0EolXomRtaiQuXUK9nP-wLUtUWqBQEh_ZsTezZ1JFjB3s3Ev8eLylVW1_G8_rxq5nRMPa-5p8BFD-3LhNmyh1veM3hFTsVvFdL1Yv69ZP7CTvLecvLUTVI0b1lJ8AbIdu-OWXu9p6q60P0Bxc21V2wlPKIwc5ZHKqxvP6InszkMVVFrwqfcE_T6Ey1KkI2JZvRXxhMIpz1q8mM6KsLSyEaTMaFuMN37M2APtPZQ1ywu6_Xt5ffl6uf324uL1ZLAyBgCetGKuq4IWnWIFu1VgNJ1SrZcmONEIaTEn3TShIN70iUaAXyWtIgcJCwYDdHXxtxq_fJ7TD90RGd_ifEtNGYSpWeNPUKpZISCaCxXY28jAeEBBgkmgGK15ej135a78gaCmNC_8z0-Utw93oTD7qDGqCbDT49GKT4e6I86p3LhrzHQHHKWhRMCpjZBfv4At3GKYUyKi1aKXolGz53d36kTIo5Jxoei6m5nrdCv9iK8uPD0x4e-f87AH8Bfwq0pw</recordid><startdate>20181113</startdate><enddate>20181113</enddate><creator>Parkin, Ashleigh</creator><creator>Man, Jennifer</creator><creator>Chou, Angela</creator><creator>Nagrial, Adnan M</creator><creator>Samra, Jaswinder</creator><creator>Gill, Anthony J</creator><creator>Timpson, Paul</creator><creator>Pajic, Marina</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-3871-3829</orcidid></search><sort><creationdate>20181113</creationdate><title>The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma</title><author>Parkin, Ashleigh ; Man, Jennifer ; Chou, Angela ; Nagrial, Adnan M ; Samra, Jaswinder ; Gill, Anthony J ; Timpson, Paul ; Pajic, Marina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Abdomen</topic><topic>Adenocarcinoma</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Chemoresistance</topic><topic>Clinical trials</topic><topic>Gene expression</topic><topic>Genomics</topic><topic>Lymphatic system</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>molecular classification</topic><topic>Mutation</topic><topic>Pain</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Review</topic><topic>tailored therapy</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parkin, Ashleigh</creatorcontrib><creatorcontrib>Man, Jennifer</creatorcontrib><creatorcontrib>Chou, Angela</creatorcontrib><creatorcontrib>Nagrial, Adnan M</creatorcontrib><creatorcontrib>Samra, Jaswinder</creatorcontrib><creatorcontrib>Gill, Anthony J</creatorcontrib><creatorcontrib>Timpson, Paul</creatorcontrib><creatorcontrib>Pajic, Marina</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Open Access Journals</collection><jtitle>Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parkin, Ashleigh</au><au>Man, Jennifer</au><au>Chou, Angela</au><au>Nagrial, Adnan M</au><au>Samra, Jaswinder</au><au>Gill, Anthony J</au><au>Timpson, Paul</au><au>Pajic, Marina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma</atitle><jtitle>Diseases</jtitle><addtitle>Diseases</addtitle><date>2018-11-13</date><risdate>2018</risdate><volume>6</volume><issue>4</issue><spage>103</spage><pages>103-</pages><issn>2079-9721</issn><eissn>2079-9721</eissn><abstract>Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. Our increasing understanding of the genomic heterogeneity of cancer suggests that the failure of definitive clinical trials to demonstrate efficacy in the majority of cases is likely due to the low proportion of responsive molecular subtypes. As a consequence, novel treatment strategies to approach this disease are urgently needed. Significant developments in the field of precision oncology have led to increasing molecular stratification of cancers into subtypes, where individual cancers are selected for optimal therapy depending on their molecular or genomic fingerprint. This review provides an overview of the current status of clinically used and emerging treatment strategies, and discusses the advances in and the potential for the implementation of precision medicine in this highly lethal malignancy, for which there are currently no curative systemic therapies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30428574</pmid><doi>10.3390/diseases6040103</doi><orcidid>https://orcid.org/0000-0002-3871-3829</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2079-9721
ispartof Diseases, 2018-11, Vol.6 (4), p.103
issn 2079-9721
2079-9721
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e79a8988ae334d61a082632833f8acf3
source Publicly Available Content Database; PubMed Central
subjects Abdomen
Adenocarcinoma
Biomarkers
Cancer therapies
Cell cycle
Chemoresistance
Clinical trials
Gene expression
Genomics
Lymphatic system
Malignancy
Medical prognosis
Metastasis
molecular classification
Mutation
Pain
Pancreatic cancer
Patients
Precision medicine
Review
tailored therapy
Tumors
Ultrasonic imaging
title The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T21%3A01%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Evolving%20Understanding%20of%20the%20Molecular%20and%20Therapeutic%20Landscape%20of%20Pancreatic%20Ductal%20Adenocarcinoma&rft.jtitle=Diseases&rft.au=Parkin,%20Ashleigh&rft.date=2018-11-13&rft.volume=6&rft.issue=4&rft.spage=103&rft.pages=103-&rft.issn=2079-9721&rft.eissn=2079-9721&rft_id=info:doi/10.3390/diseases6040103&rft_dat=%3Cproquest_doaj_%3E2133823336%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3323-3b489e60ce8cb3859b9fe8959850cdc22c0e927458e2406e28e2d2a018ef2af83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2582798408&rft_id=info:pmid/30428574&rfr_iscdi=true